Company intelligence / Profile preview

Palla Pharma

Melbourne, Victoria, Australia

Ownership: Private
Development stage: Other

Overview

TPI is a licensed pharmaceutical manufacturer producing narcotic raw materials and active pharmaceutical ingredients. The company achieved 10-fold production increases in 2016 and was targeting 100 tonnes of narcotic raw material production by 2019 and 200 tonnes by 2021.

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Chemicals & Materials

Partnerships

Sterling Pharma (toll manufacturing agreement for Codeine Phosphate for UK market)Buchang Pharma (strategic alliance)

Beyond the preview

Go deeper on Palla Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Palla Pharma.

Explore the full profile